Darovasertib + Crizotinib for Uveal Melanoma

This trial tests two medications, darovasertib and crizotinib, to determine if they can prevent uveal melanoma (a type of eye cancer) from returning after initial treatment. The study involves two groups: one receives the drug combination, while the other undergoes standard follow-up care. Individuals who have completed treatment for uveal melanoma and are at high risk for recurrence might be suitable candidates for this trial. Those who have undergone primary local therapy, such as enucleation or proton beam therapy, and show no signs of cancer spreading may find this trial appropriate. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

A previous study showed that the combination of darovasertib and crizotinib was generally well-tolerated by patients with metastatic uveal melanoma. Serious side effects related to the treatment occurred in 9.2% of patients, indicating they were uncommon. One treatment-related death occurred, but a similar incident happened in a comparison group, suggesting it is not unique to this treatment.

The combination treatment demonstrated a good safety profile, allowing patients to continue without major issues. Earlier studies suggested that the treatment was safe for individuals with this type of cancer.

Researchers are excited about the combination of Darovasertib and Crizotinib for treating uveal melanoma because it offers a new approach compared to existing treatments like surgery, radiation, and traditional chemotherapy. While most treatments aim to remove or destroy the cancer, this combination specifically targets and interrupts key pathways that cancer cells use to grow and spread. Darovasertib inhibits proteins involved in cell growth, while Crizotinib targets enzymes that help cancer cells thrive. Together, they provide a more precise attack on the cancer, potentially leading to more effective outcomes with fewer side effects.

This trial will evaluate the combination of darovasertib and crizotinib for treating uveal melanoma, a type of eye cancer. Studies have shown that using these drugs together appears promising, helping patients live longer without their cancer worsening. In earlier studies with patients whose cancer had spread, participants lived for an average of 21.1 months, which is longer than usual. The FDA has recognized this treatment as a breakthrough for certain stages of this cancer. Overall, earlier studies have proven the combination to be both effective and safe. Participants in this trial will receive either the treatment combination or standard care observation and follow-up.¹³⁴⁵⁶